Spots Global Cancer Trial Database for Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Official Title: Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Study ID: NCT01794845

Conditions

Squamous Cell Carcinoma

Head and Neck Cancer

Recurrent Disease

Interventions

Erbitux

Taxotere

Low Dose Fractionated Radiation Therapy

Study Description

Brief Summary: Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.

Detailed Description: The investigator's approach is based on the following reasons: * Low dose hyper-radiation sensitivity response will be significantly enhanced in Taxotere- induced G2/M cell cycle arrest. * LDFRT will render enhanced bax activation mediated mode of cell death. * Erbitux will arrest the cells in G1/G0 phase leading to p21-mediated mode of cell death. * The toxicity profile is expected to be minimal. Based on the above mentioned reasons, we propose this novel schema of treatment in recurrent SCCHN.